BiomX announces the Company will present further data from BiomX’s Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in two sessions at the North American Cystic Fibrosis Conference in Boston. First, a poster titled “Safety and efficacy of nebulized phage in CF patients with chronic Pseudomonas aeruginosa pulmonary infection: A phase 1b/2a randomized, double-blind placebo-controlled, multicenter study” will be displayed with lead author present on Friday, September 27, 2024, 1:15-2:15 PM ET. On Saturday, September 28, 2024, Urania Rappo, MD will discuss the findings in Workshop 38 “Epidemiology & Management of Infection in CF.”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHGE:
- BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
- BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- BiomX to present cinical trial data for BX004 at ERS
- UPDATE ON UNITS – BiomX Inc. Announces 1-for-10 Reverse Stock Split
- BiomX announces 1-for-10 reverse stock split
Questions or Comments about the article? Write to editor@tipranks.com